Post Profile






Immunotherapy: Promising results in first & second line treatment of metastatic bladder cancer

(European Society for Medical Oncology) Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO 2016 Congress in Copenhagen.
read more

share

Related Posts


Niraparib significantly improves outcome of ovarian cancer patients in landmark trial

Health : EurekAlert: Health

(European Society for Medical Oncology) The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first ti...

Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma

Health : EurekAlert: Health

(European Society for Medical Oncology) Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the fir...

Biothera To Present Research Results At European Society For Medical Oncology World Gastrointestinal Congress

Health : Medical News Today

Biothera has been accepted to present data from its Phase II clinical trial in stage IV KRAS-mutant colorectal cancer at the European Society for Medical Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer June 22-25 in B...

Phase III Trial Results For 2nd Line Treatment Of Metastatic Colorectal Cancer To Be Presented At ESMO 13th World Congress On Gastrointestinal Cancer

Health : Medical News Today

Results of a large, multi-national phase III trial for second-line treatment of metastatic colorectal cancer will be presented for the first time at the ESMO 13th World Congress on Gastrointestinal Cancer, beginning June 22 2011 in ...

Thousands of melanoma patients in Europe have no access to new life saving drugs

Health : EurekAlert: Health

(European Society for Medical Oncology) Over 5,000 patients with metastatic melanoma in Europe are denied access to new, life saving drugs every year, according to a survey presented at the ESMO 2016 Congress in Copenhagen.

Comments


Copyright © 2016 Regator, LLC